Cargando…
Author Correction: Calcium channel blocker amlodipine besylate therapy is associated with reduced case fatality rate of COVID-19 patients with hypertension
A Correction to this paper has been published: https://doi.org/10.1038/s41421-021-00267-0
Autores principales: | Zhang, Lei-Ke, Sun, Yuan, Zeng, Haolong, Wang, Qingxing, Jiang, Xiaming, Shang, Wei-Juan, Wu, Yan, Li, Shufen, Zhang, Yu-Lan, Hao, Zhao-Nian, Chen, Hongbo, Jin, Runming, Liu, Wei, Li, Hao, Peng, Ke, Xiao, Gengfu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Singapore
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8093281/ https://www.ncbi.nlm.nih.gov/pubmed/33941764 http://dx.doi.org/10.1038/s41421-021-00267-0 |
Ejemplares similares
-
Calcium channel blocker amlodipine besylate therapy is associated with reduced case fatality rate of COVID-19 patients with hypertension
por: Zhang, Lei-Ke, et al.
Publicado: (2020) -
Formulation and Evaluation of S-(-)-Amlodipine Besylate and Nebivolol Hydrochloride Tablets
por: Shaikh, S.A, et al.
Publicado: (2010) -
Chronic unilateral chemosis following the use of amlodipine besylate
por: Kim, Kyeong Hwan, et al.
Publicado: (2014) -
Efficacy of amlodipine besylate and Valsartan for the treatment of mild to moderate hypertension
por: Wang, Xiao-ou, et al.
Publicado: (2019) -
Kinetic spectrophotometric method for determination of amlodipine besylate in its pharmaceutical tablets
por: Mahmoud, Ashraf M., et al.
Publicado: (2012)